GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenaya Therapeutics Inc (NAS:TNYA) » Definitions » Price-to-Free-Cash-Flow

Tenaya Therapeutics (Tenaya Therapeutics) Price-to-Free-Cash-Flow : N/A (As of May. 23, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Tenaya Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-05-23), Tenaya Therapeutics's share price is $4.42. Tenaya Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.34. Hence, Tenaya Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Tenaya Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

TNYA's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.86
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Tenaya Therapeutics's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.36. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.34.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 5.60% per year.

During the past 5 years, Tenaya Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 5.60% per year. The lowest was -40.90% per year. And the median was -17.65% per year.


Tenaya Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Tenaya Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenaya Therapeutics Price-to-Free-Cash-Flow Chart

Tenaya Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
- - - - -

Tenaya Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Tenaya Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Tenaya Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenaya Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenaya Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Tenaya Therapeutics's Price-to-Free-Cash-Flow falls into.



Tenaya Therapeutics Price-to-Free-Cash-Flow Calculation

Tenaya Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=4.42/-1.341
=N/A

Tenaya Therapeutics's Share Price of today is $4.42.
Tenaya Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.34.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Tenaya Therapeutics  (NAS:TNYA) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Tenaya Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Tenaya Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Tenaya Therapeutics (Tenaya Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
171 Oyster Point Boulevard, Suite 500, South San Francisco, CA, USA, 94080
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
Executives
Timothy Hoey officer: Chief Scientific Officer C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, 5TH FLR., SOUTH SAN FRANCISCO CA 94080
Leone D Patterson officer: Chief Fin and Bus. Officer
Whittemore Tingley officer: Chief Medical Officer C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Faraz Ali director, officer: Chief Executive Officer C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BLVD., 5TH FLR., SOUTH SAN FRANCISCO Z4 94080
David V Goeddel director, 10 percent owner C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii Gp, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Amy L. Burroughs director TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Column Group Iii, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Opportunity Iii Gp, Lp 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Tcg Opportunity Iii Gp, Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Column Group Opportunity Iii, Lp 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Deepak Srivastava director C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Column Group Iii-a, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Eli Casdin director 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc director 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019

Tenaya Therapeutics (Tenaya Therapeutics) Headlines